首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
【24h】

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

机译:更新的分子检测指南,用于选择肺癌患者的肺癌患者,靶向酪氨酸激酶抑制剂来自美国病理学家学院,国际肺癌研究协会和分子病理学协会

获取原文
获取原文并翻译 | 示例
       

摘要

Context: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing.
机译:背景信息:2013年,美国病理学家学院发表了基于证据的指导,国际肺癌研究协会和分子病理协会设定肺癌分子分析标准的协会,以指导治疗决策 靶向抑制剂。 新的证据促使评估额外的实验室技术,有靶基因,患者群体和肿瘤类型进行测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号